Epidemiology, antibiotic susceptibility, and serotype distribution of Streptococcus pneumoniae associated with invasive pneumococcal disease in British Columbia - A call to strengthen public health pneumococcal immunization programs

Canadian Journal of Infectious Diseases

Volumn 14, Issue 5, 2003, Pages 261-266

  Bigham, Mark ^a   Patrick, David M ^b   Bryce, Elizabeth ^c,d   Champagne, Sylvie ^d   Shaw, Carol ^b   Wu, Wrency ^b   Ng, Helen ^b   Roscoe, Diane ^c,d   Roy, Jacques ^d,e   Isaac Renton, Judy ^b,d  

^a CANADIAN BLOOD SERVICES   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^d British Columbia Chapter   (Canada)

^e ROYAL COLUMBIAN HOSPITAL   (Canada)

Author keywords

Antibiotic susceptibility; Immunization; Serotype; Streptococcus pneumoniae

Indexed keywords

CEFTRIAXONE; CEFUROXIME; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; HEPTAVALENT PNEUMOCOCCUS CONJUGATE VACCINE; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PENICILLIN DERIVATIVE; PNEUMOCOCCUS VACCINE; PPV 23; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CANADA; CHILD; FEMALE; GENDER; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; IMMUNIZATION; INVASIVE PNEUMOCOCCAL DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONHUMAN; PUBLIC HEALTH; RISK FACTOR; SEROTYPE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

EID: 0242556623     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2003/924325     Document Type: Article

References (31)

1. CDC. Prevention of Pneumococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(RR08):1-24.
2. Health Canada. Preventing Pneumococcal Disease: A Canadian Consensus Conference - 16-18 February 1998. Cdn J Infect Dis 1999;9(Suppl A):4A-10A.
3. CDC. Preventing Pneumococccal Disease Among Infants and Young Children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2000;49(RR-9):1-35.
4. Bjornson G, Scheifele D, Binder F, Talling D. Population-based incidence rate of invasive pneumococcal disease in children: Vancouver, 1994-1998. CCDR 2000;26-18:149-51.
5. National Advisory Committee on Immunization. Canadian Immunization Guide, 6th edn. Ottawa: Canadian Medical Association, 2002:177-84.
6. Gardner P, Schaffner W. Immunization of adults. N Engl J Med 1993;328:1252-8.
7. McGeer A, Green K, Landry L, et al. Assessing the potential impact of vaccination programs on invasive pneumococcal disease: Data from population-based surveillance. Cdn J Infect Dis 1999;9(Suppl A):24A-26A.
8. National Centre for Streptococcus. Annual Report for April 1, 1999 to March 31 2000. 〈http://www2.provlab.ab.ca/bugs/vlab/ncs/ar2000_2.pdf〉 (Version current at September 4, 2003).
9. Tang K, Green A, McGeer K, et al. Antibiotic resistance trends in Canadian strains of Streptococcus pneumoniae: Results from 9 consecutive years of surveillance. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, Sep 29, 2002. (Abst)
10. Blondeau JM, Vaughan D. A review of antimicrobial resistance in Canada. Can J Microbiol 2000;46(10):867-77.
11. Pelton SI, Dagan R, Gaines BM. Pneumococcal conjugate vaccines: Proceedings from an Interactive Symposium at the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Vaccine 2003;21:1562-71.
12. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th ed. Approved standard M7-A5. Wayne, Pennsylvania: National Committee for Clinical Laboratory Standards, 2000.
13. DiFabio JL, Homma A, DeQuadros C. Pan American Health Organization Epidemiologic Surveillance Network for Streptococcus pneumoniae. Microb Drug Resis 1997;3:131-3.
14. Health Canada. Pneumococcal vaccines: World Health Organization position paper. CCDR 1999;25:150-1.
15. Scheifele D, Halperin S, Pelletier L, et al. Invasive pneumococcal infections in Canadian children, 1991-1998: Implications for new vaccination strategies. Clin Infect Dis 2000;31:58-61.
16. Cadoz M. Potential and limitations of polysaccharide vaccines in infancy. Vaccine 1998;16:1391-5.
17. Lee H-J, Kang J-H, Henrichsen J, et al. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in healthy children and in children at increased risk of pneumococcal infection. Vaccine 1995;13:1533-8.
18. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187-95.
19. Rennels MB, Edwards KM, Keyserling HL, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM1197 in United States infants. Pediatrics 1998;101:604-11.
20. Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 2000;19:394-7.
21. Butler JC, Breiman RF, Lipman HB, Hofmann J, Facklam RR. Serotype distribution of Streptococcus pneumoniae infections among preschool children in the United States, 1978-1994: Implications for development of a conjugate vaccine. J Infect Dis 1995;171;885-9.
22. Mandell LA, Marrie TJ, Grossmann RF, Chow AW, Hyland RH. The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: An evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis 2000;31:383-421.
23. Quach C, Weiss K, Moore D, et al. Clinical aspects and cost of invasive Streptococcus pneumoniae infections in children: Resistant vs. susceptible strains. Int J Antimicrob Agents 2002 Aug;20:113-8.
24. Butler JC, Dowell SC, Breiman RF. Epidemiology of emerging pneumococcal drug resistance: implications for treatment and prevention. Vaccine 1998;16:1693-7.
25. Health Canada. Controlling Antimicrobial Resistance. An Integrated Action Plan for Canadians. CCDR 1997;23S7:1-32.
26. American Academy of Pediatrics, Committee on Infectious Diseases. Therapy for children with invasive pneumococcal infections. Pediatrics 1997;99:289-99.
27. Jernigan DB, Cetron MS, Breiman RF. Minimising the impact of drug-resistant Streptococcus pneumoniae (DRSP). JAMA 1996;275:206-09.
28. Fedson DS. The clinical effectiveness of pneumococcal vaccination: A brief review. Vaccine 1999;17:S85-S90.
29. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991;325:1453-60.
30. Fedson DS. Pneumococcal vaccination for older adults. The first 20 years. Drugs and Aging 1999;15(Suppl 1):21-30.
31. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270:1826-31.